IDEXX LABORATORIES INC /DE Net Cash Provided by (Used in) Investing Activities, Continuing Operations
IDEXX LABORATORIES INC /DE (IDXX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $138.60 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2019-02-15
- IDEXX LABORATORIES INC /DE net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$24.49M.
- IDEXX LABORATORIES INC /DE net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$41.49M.
- IDEXX LABORATORIES INC /DE net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$43.70M.
- IDEXX LABORATORIES INC /DE net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$29.01M.
- IDEXX LABORATORIES INC /DE net cash provided by (used in) investing activities, continuing operations for fiscal 2018 was $138.60M.
- IDEXX LABORATORIES INC /DE net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$138.69M.
- IDEXX LABORATORIES INC /DE net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$90.79M.
- IDEXX LABORATORIES INC /DE net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$308.41M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-12-31 | $138.60M 10-K · filed 2019-02-15 | |||
| 2017-12-31 | -$24.49M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15 | -$65.97M derived: sum of 2 quarters · filed 2019-02-15 | -$109.68M derived: sum of 3 quarters · filed 2019-02-15 | -$138.69M 10-K · filed 2019-02-15 |
| 2017-09-30 | -$41.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | -$85.19M derived: sum of 2 quarters · filed 2017-10-31 | -$114.20M 10-Q · filed 2017-10-31 | -$128.48M derived: sum of 4 quarters · filed 2019-02-15 |
| 2017-06-30 | -$43.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | -$72.71M 10-Q · filed 2017-08-01 | -$86.99M derived: sum of 3 quarters · filed 2019-02-15 | -$109.94M derived: sum of 4 quarters · filed 2019-02-15 |
| 2017-03-31 | -$29.01M 10-Q · filed 2017-04-28 | -$43.29M derived: sum of 2 quarters · filed 2019-02-15 | -$66.24M derived: sum of 3 quarters · filed 2019-02-15 | -$96.00M derived: sum of 4 quarters · filed 2019-02-15 |
| 2016-12-31 | -$14.28M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15 | -$37.22M derived: sum of 2 quarters · filed 2019-02-15 | -$66.99M derived: sum of 3 quarters · filed 2019-02-15 | -$90.79M 10-K · filed 2019-02-15 |
| 2016-09-30 | -$22.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | -$52.71M derived: sum of 2 quarters · filed 2017-10-31 | -$76.51M 10-Q · filed 2017-10-31 | -$102.52M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | -$29.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | -$53.56M 10-Q · filed 2017-08-01 | -$79.58M derived: sum of 3 quarters · filed 2018-02-16 | -$134.38M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | -$23.80M 10-Q · filed 2017-04-28 | -$49.81M derived: sum of 2 quarters · filed 2018-02-16 | -$104.62M derived: sum of 3 quarters · filed 2018-02-16 | -$171.59M derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | -$26.01M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | -$80.82M derived: sum of 2 quarters · filed 2018-02-16 | -$147.79M derived: sum of 3 quarters · filed 2018-02-16 | -$308.41M 10-K · filed 2018-02-16 |
| 2015-09-30 | -$54.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | -$121.77M derived: sum of 2 quarters · filed 2016-11-01 | -$282.39M 10-Q · filed 2016-11-01 | -$318.01M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | -$66.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-02 | -$227.59M 10-Q · filed 2016-08-02 | -$263.20M derived: sum of 3 quarters · filed 2017-02-17 | |
| 2015-03-31 | -$160.62M 10-Q · filed 2016-04-29 | -$196.24M derived: sum of 2 quarters · filed 2017-02-17 | ||
| 2014-12-31 | -$35.62M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | -$80.41M 10-K · filed 2017-02-17 | ||
| 2014-09-30 | -$44.80M 10-Q · filed 2015-10-28 | |||
| 2013-12-31 | -$86.06M 10-K · filed 2016-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |